AU2011263493B2 - Crystalline forms of thalidomide and processes for their preparation - Google Patents

Crystalline forms of thalidomide and processes for their preparation Download PDF

Info

Publication number
AU2011263493B2
AU2011263493B2 AU2011263493A AU2011263493A AU2011263493B2 AU 2011263493 B2 AU2011263493 B2 AU 2011263493B2 AU 2011263493 A AU2011263493 A AU 2011263493A AU 2011263493 A AU2011263493 A AU 2011263493A AU 2011263493 B2 AU2011263493 B2 AU 2011263493B2
Authority
AU
Australia
Prior art keywords
thalidomide
anhydrous
crystalline
process according
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011263493A
Other languages
English (en)
Other versions
AU2011263493A1 (en
AU2011263493A8 (en
Inventor
Vinayak Govind Gore
Sandeep Mekde
Madhukar Patil
Vinay Kumar Shukla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of AU2011263493A1 publication Critical patent/AU2011263493A1/en
Publication of AU2011263493A8 publication Critical patent/AU2011263493A8/en
Application granted granted Critical
Publication of AU2011263493B2 publication Critical patent/AU2011263493B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2011263493A 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation Ceased AU2011263493B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
IN1758/MUM/2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (3)

Publication Number Publication Date
AU2011263493A1 AU2011263493A1 (en) 2013-01-10
AU2011263493A8 AU2011263493A8 (en) 2013-02-21
AU2011263493B2 true AU2011263493B2 (en) 2015-08-06

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011263493A Ceased AU2011263493B2 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Country Status (8)

Country Link
US (2) US20130143923A1 (OSRAM)
EP (1) EP2580205A1 (OSRAM)
JP (1) JP2013528206A (OSRAM)
CN (1) CN103068812A (OSRAM)
AU (1) AU2011263493B2 (OSRAM)
CA (1) CA2801835A1 (OSRAM)
NZ (1) NZ604011A (OSRAM)
WO (1) WO2011154739A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
BR112015031291A2 (pt) * 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
CN1164586C (zh) * 2002-10-28 2004-09-01 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ITMI20041113A1 (it) * 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARINI, J.P. ET AL "Solid state evaluation of some thalidomide raw materials" International Journal of Pharmaceutics (2009) 372:17-23 *
Ubersetzung der "Product Information" (Produktinformation) zu Thalidomide Pharmion 50mg Hartkapseln - Version 1 23 August 2004 *

Also Published As

Publication number Publication date
US20150218126A1 (en) 2015-08-06
NZ604011A (en) 2015-04-24
EP2580205A1 (en) 2013-04-17
AU2011263493A1 (en) 2013-01-10
AU2011263493A8 (en) 2013-02-21
JP2013528206A (ja) 2013-07-08
CN103068812A (zh) 2013-04-24
US20130143923A1 (en) 2013-06-06
CA2801835A1 (en) 2012-12-15
WO2011154739A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
AU2011263493B2 (en) Crystalline forms of thalidomide and processes for their preparation
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
JP6607780B2 (ja) Ｌｆａ−１阻害剤およびその多形
US20110263649A1 (en) Crystalline form of lenalidomide and a process for its preparation
WO2020112941A2 (en) Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
JP2009514988A (ja) イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
JP2009537603A (ja) ５−アミノ−３−（２’，３’−ジ−Ｏ−アセチル−ベータ−Ｄ−リボフラノシル）−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンのマレイン酸塩のＡ型及びＢ型結晶形
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
CA2703230A1 (en) Novel crystalline forms
US20080015197A1 (en) Process for the preparatrion of zopiclone
JP2008539278A (ja) 結晶性ロスバスタチンカルシウム
DK2532651T3 (en) Synthesis process and the crystal form of 4- {3- [cis-hexahydrocyclopenta [c] pyrrole-2 (1 H) -yl] propoxy} benzamide hydrochloride and the free base thereof, and the pharmaceutical compositions containing them
KR20070072588A (ko) 텔미사르탄 나트륨의 비정질형 및 다형
WO2020168144A1 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2014012480A1 (zh) 氘代ω-二苯基脲或其盐的多晶型物
EP2765131B1 (en) Process for the production of Moxonidine
WO2023222946A1 (en) Process for the preparation of cabozantinib

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 27 , NO 1 , PAGE(S) 121 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENERICS (UK) LIMITED, APPLICATION NO. 2011263493, UNDER INID (71) CORRECT THE NAME TO GENERICS (UK) LIMITED

FGA Letters patent sealed or granted (standard patent)